

Erratum:

The 1st EQAsia External Quality Assessment trial: *Escherichia coli* and *Salmonella* spp. – 2021

Issued date: December 2021

The Minimum Inhibitory Concentration (MIC) of Cefoxitin (FOX) for strain E EQASIA 21.3 (*Escherichia coli*) has been wrongly reported as 16 mg/L (Resistant). In this amendment, the MIC has been changed to **8 mg/L** and the strain categorized as **susceptible** towards Cefoxitin.

The following figures/tables have been changed accordingly. The changes are marked in **red**:

- Table 4
- Figure 2
- Figure 3
- Figure 10
- Appendix 2a: Reference values (MIC values and interpretation) – *Escherichia coli*

Table 4. Total number of antimicrobial susceptibility tests performed and percentage of correct reported and correct adjusted results in agreement with expected interpretive results (R/S). Results are from 13 HH laboratories for the *E. coli* trial.

Strain	AST in total	% correct reported	% correct adjusted
E EQASIA 21.1	170	84.7	92.4
E EQASIA 21.3	170	92.9	97.6
E EQASIA 21.4	169	95.3	97.6
E EQASIA 21.5	171	80.7	87.7
E EQASIA 21.7	170	82.9	90.6
E EQASIA 21.8	168	97.0	97.0
E EQASIA 21.9	170	87.1	94.7
E EQASIA 21.11	169	84.6	88.8

*E, *Escherichia coli*




Figure 2. Percentage of deviation in the AST interpretation (R/S) among *E. coli* strains by HH laboratories (n=13) participating in the 1st EQA in the EQAsia project. Results are categorized according to antimicrobial agent.




Figure 3. Percentage of deviation in the AST interpretation (R/S) among *E. coli* strains by HH laboratories (n=13) participating in the 1st EQA in the EQAsia project. Results are categorized by laboratory ID number.




Figure 10. Percentage of deviation in the AST interpretation (R/S) among *E. coli* strains by AH laboratories (n=10) participating in the 1st EQA in the EQAsia project. Results are categorized by laboratory ID number.

Appendix 2a: Reference values (MIC values and interpretation) – *Escherichia coli*

	Ampicillin AMP		Azithromycin AZI		Cefepime FEP		Cefotaxime FOT		FOT+clav F/C		Cefoxitin FOX		Ceftazidime TAZ		TAZ+clav T/C		Chloramphenicol CHL		Ciprofloxacin CIP	
E EQASIA 21.1	>1024	R	64	R	>32	R	>64	R	0,25/4	64	R	4	R	0,5/4	128	R	>8	R		
E EQASIA 21.3	>64	R	64	R	0,25	S	≤0,25	S	0,12/4	8	S	≤0,50	S	0,25/4	>128	R	>8	R		
E EQASIA 21.4	>64	R	8	S	>32	R	>64	R	0,12/4	4	S	4	R	0,25/4	≤8	S	≤0,015	S		
E EQASIA 21.5	>64	R	64	R	≤0,06	S	2	R	2/4	>64	R	8	R	8/4	≤8	S	0,12	R		
E EQASIA 21.7	>64	R	64	R	8	R	32	R	≤0,06/4	4	S	1	R	≤0,12/4	64	R	0,12	R		
E EQASIA 21.8	4	S	8	S	≤0,06	S	≤0,25	S	≤0,06/4	4	S	≤0,25	S	≤0,12/4	≤8	S	≤0,015	S		
E EQASIA 21.9	>64	R	8	S	32	R	>64	R	2/4	64	R	16	R	4/4	>128	R	>8	R		
E EQASIA 21.11	>64	R	16	S	0,25	S	16	R	8/4	64	R	32	R	16/4	>128	R	2	R		

R, Resistant; S, Susceptible

	Colistin COL		Ertapenem ETP		Gentamicin GEN		Imipenem IMI		Meropenem MERO		Nalidixic acid NAL		Sulfamethoxazole SMX		Tetracycline TET		Tigecycline TGC		Trimethoprim TMP	
E EQASIA 21.1	≤1	S	2	R	>32	R	0,5	S	0,5	R	>128	R	>1024	R	>64	R	≤0,25	S	>32	R
E EQASIA 21.3	≤1	S	≤0,015	S	1	S	0,25	S	≤0,03	S	>128	R	>1024	R	>64	R	≤0,25	S	>32	R
E EQASIA 21.4	≤1	S	≤0,015	S	≤0,5	S	0,25	S	≤0,03	S	≤4	S	≤8	S	≤2	S	≤0,25	S	≤0,25	S
E EQASIA 21.5	2	S	0,03	S	2	S	0,5	S	≤0,03	S	≤4	S	≤8	S	≤2	S	≤0,25	S	>32	R
E EQASIA 21.7	≤1	S	≤0,015	S	≤0,5	S	0,25	S	≤0,03	S	≤4	S	>1024	R	>64	R	≤0,25	S	>32	R
E EQASIA 21.8	≤1	S	≤0,015	S	≤0,5	S	≤0,12	S	≤0,03	S	≤4	S	≤8	S	≤2	S	≤0,25	S	≤0,25	S
E EQASIA 21.9	≤1	S	0,06	R	1	S	0,25	S	≤0,03	S	>128	R	≤8	S	>64	R	0,5	S	>32	R
E EQASIA 21.11	≤1	S	0,06	R	32	R	0,25	S	≤0,03	S	>128	R	>1024	R	>64	R	0,5	S	≤0,25	S

R, Resistant; S, Susceptible